The Multiple Myeloma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Myeloma pipeline products will significantly revolutionize the Multiple Myeloma market dynamics.  

Multiple Myeloma Overview

Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States.MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74. According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. 

The Multiple Myeloma Treatment usually includes anti-myeloma medicines to destroy the myeloma cells or control cancer when it comes back (relapses) and medicines and procedures to prevent and treat problems caused by myeloma – such as bone pain, fractures, and anemia.

Some of the key facts of the Multiple Myeloma Market Report: 

• The Multiple Myeloma market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
• In the year 2020, the total incident case of Multiple Myeloma was 70,577 cases in the 7MM countries 
• Among the 7MM countries, the United States, in 2020, accounted for 32,270 cases (the highest number) which might increase in the forecast period 
• In January 2022, Oncopeptides rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto (INN melphalan flufenamide, also called melflufen) in the United States 
• In May 2022, the European Commission granted conditional marketing authorization to CARVYKTI (ciltacabtagene autoleuceI) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies 
• Key Multiple Myeloma Companies: AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca, and others 
• Key Multiple Myeloma Therapies: Venetoclax, ABBV 383, Teclistamab, Talquetamab, REGN5458, Iberdomide, Descartes-11, and others 
• The Multiple Myeloma epidemiology based on gender analyzed that males are affected more, in case of Multiple Myeloma (MM) as compared to females 

Get a Free sample for the Multiple Myeloma Market Report 

Key benefits of the Multiple Myeloma Market report:

1. Multiple Myeloma market report covers a descriptive overview and comprehensive insight of the Multiple Myeloma Epidemiology and Multiple Myeloma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Multiple Myeloma market report provides insights on the current and emerging therapies.
3. Multiple Myeloma market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Multiple Myeloma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Multiple Myeloma market.

Discover more about therapies set to grab major Multiple Myeloma market share @ Multiple Myeloma market forecast 

Multiple Myeloma Epidemiology Segmentation:

The Multiple Myeloma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Multiple Myeloma
• Prevalent Cases of Multiple Myeloma by severity
• Gender-specific Prevalence of Multiple Myeloma
• Diagnosed Cases of Episodic and Chronic Multiple Myeloma 

Multiple Myeloma Market  

The dynamics of the Multiple Myeloma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as REGN5458, Iberdomide, and others during the forecasted period 2019-2032. 

Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiological Insights 

Multiple Myeloma Market Drivers

• Increasing incidence rate of Multiple Myeloma
• High adoption rate of newer Multiple Myeloma therapies
• Increase in the Geriatric Population

Multiple Myeloma Therapies and Key Companies

• Venetoclax: AbbVie and Roche
• ABBV 383: AbbVie
• Teclistamab: Janssen Pharmaceutical
• Talquetamab: Janssen Pharmaceutical
• REGN5458: Regeneron Pharmaceuticals
• Iberdomide: Bristol-Myers Squibb/Celgene
• Descartes-11: Cartesian Therapeutics

Scope of the Multiple Myeloma Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Multiple Myeloma Companies: AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca, and others
• Key Multiple Myeloma Therapies: Venetoclax, ABBV 383, Teclistamab, Talquetamab, REGN5458, Iberdomide, Descartes-11, and others
• Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
• Multiple Myeloma Market Dynamics:  Multiple Myeloma market drivers and Multiple Myeloma market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Multiple Myeloma Market Access and Reimbursement 

Multiple Myeloma Market Barriers

Expensive treatment options of Multiple Myeloma

Toxicities and adverse events of various Multiple Myeloma therapeutics

Table of Contents 

1. Multiple Myeloma Market Report Introduction

2. Executive Summary for Multiple Myeloma

3. SWOT analysis of Multiple Myeloma

4. Multiple Myeloma Patient Share (%) Overview at a Glance

5. Multiple Myeloma Market Overview at a Glance

6. Multiple Myeloma Disease Background and Overview

7. Multiple Myeloma Epidemiology and Patient Population

8. Country-Specific Patient Population of Multiple Myeloma 

9. Multiple Myeloma Current Treatment and Medical Practices

10. Multiple Myeloma Unmet Needs

11. Multiple Myeloma Emerging Therapies

12. Multiple Myeloma Market Outlook

13. Country-Wise Multiple Myeloma Market Analysis (2019–2032)

14. Multiple Myeloma Market Access and Reimbursement of Therapies

15. Multiple Myeloma Market Drivers

16. Multiple Myeloma Market Barriers

17.  Multiple Myeloma Appendix

18. Multiple Myeloma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Multiple Myeloma treatment, visit @ Multiple Myeloma Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/